Sector: Health Care
ACADIA PHARMACEUTICALS INC · Meeting: May 29, 2025
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Election of Three Class III Directors
Ms. Owen Adams joined as CEO in September 2024, well within the 24-month new-director exemption, so she is fully exempt from the TSR performance trigger; she brings extensive pharmaceutical commercial leadership experience from Bristol Myers Squibb and Johnson & Johnson, and no overboarding, attendance, or independence concerns apply.
Ms. Brege has served since May 2008 and the 3-year TSR gap versus the company-disclosed peer group median is only -13.6 percentage points, well below the 35-point trigger threshold for a low-positive absolute TSR; no overboarding, attendance, or other disqualifying flags are present, and she qualifies as the audit committee financial expert.
Dr. Garofalo has served since September 2020 and the 3-year TSR gap versus the peer group median is -13.6 percentage points, comfortably below the 35-point trigger threshold; she holds two public board seats (Alector and Xenon), which is within the acceptable limit, and brings deep neuroscience drug development expertise relevant to Acadia's pipeline.
All three Class III nominees pass the TSR trigger test using the company-disclosed peer group benchmark — Acadia's 3-year return of +19.4% trails the peer median by only 13.6 percentage points, well under the 35-point threshold applicable to a low-positive absolute TSR. No overboarding, attendance, independence, or qualification concerns were identified for any nominee. Catherine Owen Adams is additionally exempt as a director who joined within the past 24 months. All three directors receive a FOR vote.
CEO
Catherine Owen
Total Comp
$7,594,107
Prior Support
94%%
The prior year Say on Pay vote received approximately 94% support, signaling strong shareholder endorsement of the pay program. CEO Catherine Owen Adams's total compensation of $7,594,107 for 2024 reflects a partial-year tenure (she started September 2024) and includes a $500,000 sign-on cash bonus and a $6.6 million new-hire equity grant — context that meaningfully inflates the single-year reported figure but is consistent with market practice for incoming CEOs at companies of this size and complexity. The pay program demonstrates strong positive features: approximately 94% of the current CEO's direct compensation is variable or at-risk; performance stock awards are now tied to relative total shareholder return over a three-year period (a direct improvement made in response to shareholder feedback); annual cash bonuses are tied to objective, pre-established goals and paid out at 87% of target reflecting actual business results; a meaningful clawback policy is in place; and the company explicitly prohibits hedging and pledging. No material overpayment relative to benchmark, poor pay-mix, or pay-for-performance misalignment triggers were identified.
Auditor
Ernst & Young LLP
Tenure
10 yrs
Audit Fees
$1,701,869
Non-Audit Fees
$644,908
Ernst & Young has served since March 2015, giving it approximately 10 years of tenure — well below the 25-year threshold that would raise independence concerns. Tax fees of $644,908 represent about 38% of audit fees of $1,701,869, which is below the 50% threshold that would trigger a no vote. EY is a Big 4 firm fully appropriate for a $3.8 billion market-cap company, and no material financial restatements were identified.
Acadia's 2025 annual meeting presents a clean ballot with no significant governance concerns. All three Class III director nominees pass the TSR trigger test against the company-disclosed peer group, the auditor fee structure is well within independence thresholds at a 38% non-audit ratio after 10 years of tenure, and the executive compensation program — while featuring elevated new-hire grant values due to a CEO transition year — is predominantly performance-based with meaningful shareholder-responsive improvements and strong prior-year support of 94%.
19 companies disclosed in 2025 proxy filing